Global Focal Segmental Glomerulosclerosis (FSGS) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Focal Segmental Glomerulosclerosis (FSGS) Market Research Report 2024
Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.
According to MRAResearch’s new survey, global Focal Segmental Glomerulosclerosis (FSGS) market is projected to reach US$ 9733.1 million in 2033, increasing from US$ 6998 million in 2022, with the CAGR of 4.4% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Focal Segmental Glomerulosclerosis (FSGS) market research.
Key companies engaged in the Focal Segmental Glomerulosclerosis (FSGS) industry include Travere Therapeutics (Retrophin), Novartis, ZyVersa(Variant), Dimerix, Goldfinch Bio, ChemoCentryx, FibroGen, Pfizer and AstraZeneca, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Focal Segmental Glomerulosclerosis (FSGS) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Focal Segmental Glomerulosclerosis (FSGS) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Focal Segmental Glomerulosclerosis (FSGS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Travere Therapeutics (Retrophin)
Novartis
ZyVersa(Variant)
Dimerix
Goldfinch Bio
ChemoCentryx
FibroGen
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Calliditas
Reata (AbbVie)
Astellas Pharma
Complexa
Aurinia
Vertex Pharmaceuticals
Chinook Therapeutics
Delta 4
Langlai Science and Technology
Segment by Type
Diagnosis (Kidney Biopsy and Creatine Test)
Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Focal Segmental Glomerulosclerosis (FSGS) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Focal Segmental Glomerulosclerosis (FSGS) market is projected to reach US$ 9733.1 million in 2033, increasing from US$ 6998 million in 2022, with the CAGR of 4.4% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Focal Segmental Glomerulosclerosis (FSGS) market research.
Key companies engaged in the Focal Segmental Glomerulosclerosis (FSGS) industry include Travere Therapeutics (Retrophin), Novartis, ZyVersa(Variant), Dimerix, Goldfinch Bio, ChemoCentryx, FibroGen, Pfizer and AstraZeneca, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Focal Segmental Glomerulosclerosis (FSGS) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Focal Segmental Glomerulosclerosis (FSGS) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Focal Segmental Glomerulosclerosis (FSGS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Travere Therapeutics (Retrophin)
Novartis
ZyVersa(Variant)
Dimerix
Goldfinch Bio
ChemoCentryx
FibroGen
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Calliditas
Reata (AbbVie)
Astellas Pharma
Complexa
Aurinia
Vertex Pharmaceuticals
Chinook Therapeutics
Delta 4
Langlai Science and Technology
Segment by Type
Diagnosis (Kidney Biopsy and Creatine Test)
Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Focal Segmental Glomerulosclerosis (FSGS) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source